Pharma Stocks
-
Amylyx Pharmaceuticals (AMLX) Reports Early LUMINA Safety Data, Is The Stock Still Below Fair Value?
Amylyx Pharmaceuticals (AMLX) is back in focus after presenting early Phase 1 LUMINA trial data for its ALS candidate AMX0114…
Read More » -
REG – AIM Beximco Pharma. – Restoration
RNS Number : 9334J AIM 26 June 2026 NOTICE 26/06/2026 7:30am RESTORATION OF TRADING ON AIM BEXIMCO PHARMACEUTICALS PLC…
Read More » -
Is It Worth Considering Chugai Pharmaceutical Co., Ltd. (TSE:4519) For Its Upcoming Dividend?
It looks like Chugai Pharmaceutical Co., Ltd. (TSE:4519) is about to go ex-dividend in the next two days. The ex-dividend…
Read More » -
Helus Pharma Announces Closing of US$50 Million Underwritten Offering
Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping…
Read More » -
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Large-cap pharma is back in the deal market. AbbVie’s (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics…
Read More » -
Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play
Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it…
Read More » -
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.12, marking a +1.43% move from the previous day. The…
Read More » -
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for Setmelanotide – What’s Changed
In June 2026, Rhythm Pharmaceuticals reported preliminary six-month Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improvements in BMI,…
Read More » -
Is Ascletis Pharma (SEHK:1672) Undervalued On FDA Clearance For ASC35?
Ascletis Pharma (SEHK:1672) has attracted investor attention after receiving U.S. FDA Investigational New Drug clearance for ASC35, a once-monthly dual…
Read More » -
Deepened Boston Children’s Partnership Could Be A Game Changer For Nippon Shinyaku (TSE:4516)
Nippon Shinyaku Co., Ltd. has entered into a Sponsored Research Agreement with Boston Children’s Hospital to co-develop innovative neurology drugs,…
Read More »